ASC4FIRST试验:阿西米尼在新诊断慢性髓性白血病中展现更优疗效与安全性
ASC4FIRST是一项3期随机试验,在新诊断慢性期慢性髓性白血病(CML-CP)患者中比较阿西米尼与研究者选择的TKI(IS-TKI)。中位随访2.2年的二次分析显示,阿西米尼第96周主要分子学反应(MMR)率显著优于IS-TKI(74.1% vs 52.0%)和伊马替尼(76.2% vs 47.1%),且安全性和耐受性更优。
要点
- 阿西米尼第96周MMR率74.1%,显著优于IS-TKI的52.0%(差异22.4%,95%CI 13.6-31.3)。
- 伊马替尼分层中阿西米尼MMR率76.2%,优于伊马替尼的47.1%(差异29.7%,95%CI 17.6-41.8)。
- 因不良事件停药时间风险比显示阿西米尼优于二代TKI(HR 0.46,95%CI 0.215-0.997)。
核心结论
- 阿西米尼在新诊断CML-CP中相比IS-TKI和伊马替尼展现出更优的疗效与有利的风险获益特征。
研究设计与样本
- ASC4FIRST为3期随机试验,比较阿西米尼与研究者选择的TKI(IS-TKI)在新诊断CML-CP患者中的疗效与安全性,注册号NCT04971226。
主要发现
- 剂量降低和中断分别见于阿西米尼(18.5%;46.5%)、伊马替尼(23.2%;47.5%)和二代TKI(54.9%;63.7%)。
- 因不良事件停药时间的风险比阿西米尼 vs 二代TKI为0.46(95%CI 0.215-0.997)。
临床怎么用
- 对于新诊断CML-CP患者,阿西米尼可作为兼顾疗效与耐受性的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many patients receiving frontline tyrosine kinase inhibitors (TKIs) for chronic-phase chronic myeloid leukemia (CML-CP) experience inadequate disease control and/or adverse events (AEs) that impair quality of life. Treatments offering optimal efficacy, safety, and tolerability will support long-term therapy. In the primary analysis from the ASC4FIRST trial, a phase 3 randomized trial comparing asciminib with investigator-selected TKIs (IS-TKIs) in newly diagnosed CML-CP, asciminib demonstrated superior efficacy vs all IS-TKIs and vs imatinib in the imatinib stratum, meeting both primary objectives. In the secondary analysis (2.2 years' median follow-up), major molecular response (MMR) rate at week 96 was 74.1% with asciminib vs 52.0% with IS-TKIs (treatment difference, 22.4% [95% confidence interval (CI), 13.6-31.3]; 1-sided P< .001) and 76.2% with asciminib vs 47.1% with imatinib in the imatinib stratum (treatment difference, 29.7% [95% CI, 17.6-41.8]; 1-sided P< .001), meeting both key secondary objectives. MMR rate was 72.0% with asciminib vs 56.9% with second-generation (2G) TKIs (treatment difference, 15.1% [95% CI, 2.3-28.0]; 1-sided P< .05), suggesting possible clinical benefit, although the study was not designed to formally confirm statistical significance for this secondary end point. Safety/tolerability remained favorable with asciminib vs IS-TKIs. Dose reductions and interruptions, respectively, occurred with asciminib (18.5%; 46.5%), imatinib (23.2%; 47.5%), and 2G TKIs (54.9%; 63.7%). The hazard ratio for time to discontinuation of treatment due to AEs for asciminib vs 2G TKIs was 0.46 (95% CI, 0.215-0.997). With longer follow-up, asciminib continued to demonstrate a favorable benefit-risk profile over IS-TKIs and imatinib, supporting its potential as a treatment option for newly diagnosed CML-CP. This trial was registered at www.clinicaltrials.gov as NCT04971226.
引用
- Cortes JE, Hughes TP, Wang J, et al. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026. PMID: 41397287. doi:10.1182/blood.2025029210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。